Greetings HG,
Your critique and questions are most welcome and appreciated, though MLSC officers may be the ones who can answer your questions better than myself. I am personally convinced that they are committed to product and development and am quite understanding of the fact that developmental pharmaceutical companies have disgusting looking financials. Why CEO's of these companies pay themselves such "comfortable" salaries is really beyond me -- and quite honestly, I share that gripe with you. But I have also been impressed with the fact that MLSC pounds the pavements in search of funding and grants, and that they have positioned themselves with folks who may have the know-how, credibility and the connections to make a "go" of things. Lee Kulas wouldn't have boarded this ship if he didn't see potential, and I think that that the higher salaries may have been needed in order to attract someone of Lee Kulas' expertise and caliber. I know for quite a while there were many unpaid scientific advisors to MLSC, but they are now at that stage where they are in need of the committment that requires attractive salaries.
As for the irregular and illogical trading patterns -- I can offer you no insight whatsoever. I have pondered that one myself and I believe that there is some market maker toying.
If you do get a chance to speak with management at MLSC in regards to the questions that you have asked -- I would appreciate hearing their reply on this board. After reviewing the financials for many other developmental biotech companies, and seeing basically the same astonishingly barren balance sheets -- I really find it to be no surprise that MLSC also suffers in this respect and is dependant on funding and grants. Such is the story for biotech companies in general I 'spose. Their studies have shown statistical significance and I believe they will have no problem in finding funding, financing and support. I recently glanced at OZON's financials -- and they aren't exactly sitting pretty either, but again -- this seems to be quite typical of developmental biotechs.
And please don't thank me for unwavering support of this company -- I am actually quite casual about my investment in this company -- and am only having a bit of fun on this thread and hoping for the best, expecting the worst, and willing to take what comes. I do think MLSC's patent protection alone is a valuable asset for this company, and that the ozon combination technology is very promising. MLSC is furthest along with the dental instrument sterilization, and results have been very impressive. I'm holding for the long shot on this company and am going to put up with all the negatives and the risks associated with Medical Discoveries, as distracting as they may be -- I'm still a believer.
Best of luck to you,
Cindy |
